Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Acamprosate calcium
Drug ID BADD_D00017
Description Alcohol use disorder is responsible for a large worldwide burden of morbidity, premature mortality, and economic consequences resulting from accidents, violence, incarceration, decreased productivity, and increased healthcare spending.[A229073] Acamprosate, also known by the brand name Campral, is a drug used for the maintenance of alcohol abstinence. It is a structural analogue of the neurotransmitter γ-aminobutyric acid (GABA).[L31758] Acamprosate is the first medication specifically formulated for the maintenance of alcohol abstinence in ethanol-dependent patients after alcohol detoxification[A997], unlike [naltrexone] and [disulfiram]. It was first approved by the FDA in 2004 and initially marketed by Forest Laboratories.[L31783]
Indications and Usage For the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation
Marketing Status Prescription; Discontinued
ATC Code N07BB03
DrugBank ID DB00659
KEGG ID D02780
MeSH ID D000077443
PubChem ID 155434
TTD Drug ID D0GC2M
NDC Product Code 65096-0112; 60687-121; 0904-7213; 17337-0002; 68382-569; 70771-1057; 42291-104; 0093-5352; 50056-2006; 68462-435
Synonyms Acamprosate | Acamprostate | N-Acetylhomotaurine | N Acetylhomotaurine | Campral EC | N-Acetylhomotaurine, Magnesium (2:1) Salt | N-Acetylhomotaurine, Monolithium Salt | N Acetylhomotaurine, Monolithium Salt | N-Acetylhomotaurine, Zinc (2:1) Salt | Campral | N-Acetylhomotaurine, Monosodium Salt | N Acetylhomotaurine, Monosodium Salt | Sodium Acetylhomotaurine | Acetylhomotaurine, Sodium | Zulex | Acamprosate Calcium | Calcium Acetylhomotaurine | Acetylhomotaurine, Calcium | Calcium Acetylhomotaurinate | Acetylhomotaurinate, Calcium | N-Acetylhomotaurine, Calcium (2:1) Salt | Calcium Acetyl Homotaurinate | Acetyl Homotaurinate, Calcium | N-Acetylhomotaurine, Monopotassium Salt | N Acetylhomotaurine, Monopotassium Salt | Aotal | Regtect
Chemical Information
Molecular Formula C10H20CaN2O8S2
CAS Registry Number 77337-73-6
SMILES CC(=O)NCCCS(=O)(=O)[O-].CC(=O)NCCCS(=O)(=O)[O-].[Ca+2]
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Photosensitivity reaction23.03.09.003--
Pneumonia11.01.09.003; 22.07.01.003--Not Available
Pollakiuria20.02.02.007--
Polyuria20.02.03.002--Not Available
Pruritus23.03.12.001--
Psoriasis10.02.01.036; 23.03.14.002--Not Available
Pulmonary embolism22.06.02.001; 24.01.06.001--Not Available
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Rash maculo-papular23.03.13.004--
Rectal haemorrhage07.12.03.001; 24.07.02.018--
Rheumatoid arthritis10.04.06.001; 15.01.03.001--Not Available
Rhinitis11.01.13.004; 22.07.03.006--
Salivary hypersecretion07.06.01.009--Not Available
Seizure17.12.03.001--
Sexual dysfunction19.08.05.002; 21.03.02.003--Not Available
Somnolence17.02.04.006; 19.02.05.003--
Sudden death02.03.04.013; 08.04.01.003--
Suicidal ideation19.12.01.003--
Suicide attempt19.12.01.004--
Thinking abnormal17.02.05.023; 19.10.03.001--Not Available
Thirst08.01.09.021; 14.03.02.007--Not Available
Thrombocytopenia01.08.01.002--Not Available
Tinnitus04.04.01.002; 17.04.07.004--
Torticollis15.05.04.003; 17.01.03.003--Not Available
Tremor17.01.06.002--
Urinary incontinence17.05.01.008; 20.02.02.010--
Urinary tract infection11.01.14.004; 20.08.02.001--
Urticaria10.01.06.001; 23.04.02.001--
Vaginal infection11.01.10.002; 21.14.02.002--
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages